Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43974   clinical trials with a EudraCT protocol, of which   7312   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2016-003961-25
    Sponsor's Protocol Code Number:TOZ-CL06
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2017-04-27
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-003961-25
    A.3Full title of the trial
    A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off”
    Estudio multicéntrico abierto para evaluar la seguridad y tolerabilidad de tozadenant como terapia adyuvante para pacientes con la Enfermedad de Parkinson tratados con levodopa que experimentan deterioro de fin de dosis
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing "wearing off"
    A.4.1Sponsor's protocol code numberTOZ-CL06
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03051607
    A.5.4Other Identifiers
    Name:IND NumberNumber:78230
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBiotie Therapies
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBiotie Therapies
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAMS Advanced Medical Services
    B.5.2Functional name of contact pointClinical Operations
    B.5.3 Address:
    B.5.3.1Street AddressAm Exerzierplatz 2
    B.5.3.2Town/ cityMannheim
    B.5.3.3Post code68167
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+4962170095 100
    B.5.5Fax number+4962170095 140
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nametozadenant
    D.3.2Product code TOZ
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNtozadenant
    D.3.9.1CAS number 870070-55-6
    D.3.9.2Current sponsor codeTOZ
    D.3.9.3Other descriptive nameTOZADENANT
    D.3.9.4EV Substance CodeSUB130095
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Parkinson's Disease
    Enfermedad de Parkinson
    E.1.1.1Medical condition in easily understood language
    Parkinson's Disease
    Enfermedad de Parkinson
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level LLT
    E.1.2Classification code 10013113
    E.1.2Term Disease Parkinson's
    E.1.2System Organ Class 100000004852
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the safety and tolerability of tozadenant in levodopa-treated PD patients experiencing motor fluctuations
    Evaluar la seguridad y tolerabilidad de tozadenant en pacientes afectados de EP que reciben tratamiento con levodopa y que experimentan fluctuaciones motoras
    E.2.2Secondary objectives of the trial
    To evaluate the effects of tozadenant on the occurrence of daytime drowsiness, impulsive behavior, and suicidality.
    Evaluar los efectos de tozadenant en la aparición de somnolencia diurna, comportamiento impulsivo y tendencias suicidas
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    PK sub-study - not conducted in European sites
    E.3Principal inclusion criteria
    1. Provide written informed consent.
    2. Patient is considered reliable and capable of adhering to the protocol according to the judgment of the investigator.
    3. Patient has a documented history of idiopathic Parkinson’s disease consistent with the UK Parkinson’s Disease Society Brain Bank Diagnostic criteria prior to the Screening Visit.
    4. Patient has a PD duration of at least 3 years from diagnosis.
    5. Patient has a modified Hoehn and Yahr stage 2–4 when in OFF state (estimated) and ≤ 3 in ON state.
    6. Patient is male or female and 30–80 years old (inclusive) at Screening.
    7. Patient must have a good response to levodopa in the opinion of the investigator, be taking at least four doses of a levodopa-containing medication per day, and at least one other concomitant anti PD medication (dopamine agonists, MAO-B inhibitors, anticholinergic agents, amantadine or entacapone).
    8. Patient is maintained on a regimen of permitted anti-PD medications that has been stable for at least 4 weeks prior to Screening.
    9. Patients must have been taking a levodopa-containing anti-PD medication continuously for at least the previous 12 months and must be currently experiencing end-of-dose “wearing-off” with at least 2.5 hours of OFF time per day as confirmed by a 3-day Baseline diary.
    10. Patient must have achieved the following results for PD diary training, practice diary collection, and Baseline diary recordings:
    a. During a diary concordance session with an approved PD diary trainer/rater (minimum 2.5 hours), patient achieved at least 80% overall diary concordance including at least 1 OFF interval.
    b. Returned a valid 3 day (i.e., 3 consecutive 24 hour periods) practice diary.
    c. Returned valid diary recordings for each of the 3 consecutive days preceding the Baseline Visit that indicated at least 2.5 hours of OFF time on each of the 3 days.
    11. Contraception:
    a. Women of childbearing potential must use an acceptable method of contraception starting 4 weeks prior to study drug administration and for a minimum of 1 month after study completion. Otherwise, women must be postmenopausal (at least 1year absence of vaginal bleeding or spotting, and confirmed by follicle stimulating hormone [FSH] ≥ 40 mIU/mL [or ≥ 40 IU/L] if less than 2 years postmenopausal) or be surgically sterile.
    b. Men with a potentially fertile partner must have had a vasectomy or be willing to use an acceptable method of contraception for the duration of the study and for 3 months after study drug discontinuation.
    For men and women: Acceptable methods of contraception include use of a condom with spermicide; oral, implantable or injectable contraceptives; intrauterine device (IUD); diaphragm with spermicide; or, diaphragm with condom.
    1. El paciente recibe toda la información necesaria y se le concede un período de tiempo amplio para considerar su participación en este estudio y da su consentimiento informado por escrito
    2. El paciente se considera fiable y capaz de cumplir con el protocolo (por ejemplo, comprender y completar los diarios), con el calendario de visitas y con las instrucciones de administración del tratamiento, según el criterio de los investigadores.
    3.El paciente cuenta con un historial documentado de la Enfermedad de Parkinson idiopática conforme a los criterios clínicos del Banco de Cerebros de la Sociedad de la Enfermedad de Parkinson de Reino Unido anterior a la visita de selección.
    4. El paciente padece de EP desde hace al menos tres años.
    5. El paciente tiene un estado 2–4 de Hoehn y Yahr modificado en estado “off” (aproximadamente) y menor o igual a 3 en estado “on”.
    6. El paciente es un hombre o mujer de entre 30 y 80 años (ambos incluidos) en el momento de la selección.
    7. El paciente debe mostrar una buena respuesta a la levodopa, según el criterio del investigador, y debe recibir como mínimo cuatro dosis diarias de tratamiento con levodopa y al menos otro tratamiento concomitante para la EP (agonistas dopaminérgicos, inhibidores de MAO-B, agentes anticolinérgicos, amantadina o entacapona).
    8. El paciente mantiene un régimen estable de tratamientos para la EP permitidos durante un mínimo de cuatro semanas antes de la selección.
    9. El paciente debe haber tomado un tratamiento para la EP con levodopa de forma continua durante un mínimo de 12 meses antes de la selección y debe experimentar deterioro de fin de dosis en la actualidad, con un período “off” mínimo de 2,5 horas por día, confirmado por el diario basal del estudio de tres días.
    10. El paciente debe obtener los siguientes resultados en la formación sobre diarios de EP, la recogida de diarios de práctica y los registros del diario basal del estudio:
    a.Durante una sesión de concordancia de diarios con un formador/evaluador certificado sobre diarios de EP (con una duración mínima de 2,5 horas), el paciente alcanzó una concordancia total del diario de al menos un 80 %, incluyendo al menos un intervalo “off”.
    b. Entregó un diario de práctica de tres días (es decir, tres períodos consecutivos de 24 horas) válido.
    c. Entregó registros de diarios válidos para los tres días consecutivos previos a la visita basal que incluyesen como mínimo períodos en estado “off” de 2,5 horas cada día.
    11. Anticonceptivos:
    a. Las mujeres fértiles deben utilizar un método anticonceptivo aceptable* cuatro semanas antes de la administración del fármaco en estudio y durante un período mínimo de un mes tras la finalización del estudio. De no ser así, las mujeres deben ser postmenopáusicas (con una ausencia de hemorragia o manchado vaginal de al menos un año; si se trata de una menopausia de menos de dos años, deberá confirmarse con un nivel de la hormona folículo estimulante FSH ≥ 40 mUI/ml [o ≥ 40 UI/L]) o deben estar esterilizadas quirúrgicamente.
    b. Los hombres con pareja potencialmente fértil deben haber recibido una vasectomía o estar dispuestos a utilizar un método anticonceptivo aceptable durante todo el estudio y tres meses después de la discontinuación del fármaco en estudio.
    Para hombres y mujeres: los métodos anticonceptivos aceptables incluyen la utilización de preservativo con espermicida; anticonceptivos orales, implantables o inyectables; dispositivo intrauterino (DIU); diafragma con espermicida; o, diafragma con preservativo.
    E.4Principal exclusion criteria
    1. Patient previously participated in any study with tozadenant.
    2. Patient is currently participating in or has participated in another study and received an IMP within 5 half-lives of the IMP.
    3. Patient has any form of secondary or atypical parkinsonism (e.g., drug-induced, post stroke).
    4. Body mass index (BMI) greater than 40.
    5. QTcF interval of ≥ 500 msec at Screening (Visit 1) or the patient has an average QTcF interval ≥ 450 msec for males or ≥ 470 msec for females at Baseline (Visit 2).
    6. Known diagnosis of malignant melanoma.
    7. History of neurosurgical intervention for PD, except for the placement of deep brain stimulator electrodes at least 12 months or greater prior to screening; subjects with DBS must not be experiencing any clinically meaningful side effects related to the procedure, the device, or stimulation.
    8. Grade 2 hypertension (supine systolic BP ≥ 160 or diastolic BP ≥ 100 mmHg), treated or untreated
    9. Patient with a history of hypertensive crisis unless the underlying cause has been removed .
    10. Patient has a history of chronic alcohol or drug abuse within the last 2 years.
    11. Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®, within 4 weeks prior to Screening or is likely to require any of these drugs during the study.
    12. Current treatment with antipsychotics; however, quetiapine administered at doses of ≤ 100 mg per day and pimavanserin are permitted if the patient has been on a stable daily dose for at least 4 weeks before Screening. PRN (as needed) dosing is not permitted.
    13. Patient has taken digoxin within 4 weeks prior to Screening or is likely to require digoxin during the study.
    14. Hyperthyroidism or hypothyroidism, unless all of the following conditions are met:
    a. Patient has received a stable dose of thyroid medication for at least 3 months before the Baseline Visit.
    b. TSH concentrations are in the normal range (± 10% as a window either side of the normal range).
    c. Patient is clinically euthyroid.
    15. Any out-of-range laboratory values at Screening that have not been reviewed and documented as not clinically significant by the investigator.
    16. A score of < 26 on the Mini-Mental State Examination, Second Edition (MMSE-II) at the Screening Visit.
    17. Patients with a current episode of major depression. Patients receiving treatment for depression with antidepressants may be enrolled if they have been on a stable daily dose of the antidepressant for at least 8 weeks before the Baseline Visit.
    18. Patient has a recent history of suicide attempt (defined as an active, interrupted or aborted attempt within the past 5 years), or reports suicidal ideation in the past 6 months as indicated by a positive response (‘Yes’) to either Question 4 or Question 5 of the C-SSRS performed at the Screening or Baseline Visit.
    19. Patient has evidence of an impulse control disorder (ICD) (i.e., one or more positive modules) according to the Modified Minnesota Impulse Disorders Interview (mMIDI) unless a structured clinical interview performed during Screening confirms that the patient does not have an ICD.
    20. Patient is currently lactating or pregnant or planning to become pregnant during the duration of the study.
    21. Patient has a known hypersensitivity to any components of the IMP or excipients.
    22. Any other condition or clinically significant abnormal findings on the physical or neurological examination, psychiatric and medical history, at Screening or at Baseline that, in the opinion of the investigator, would make the patient unsuitable for the study or put the patient at additional risk or prejudice evaluation of safety and efficacy of the IMP.
    23. Patients with alanine transaminase (ALT) or aspartate transaminase (AST) ≥3x upper limit of normal (ULN), or total bilirubin ≥1.5x ULN, at Screening.
    24. Patients with a history of hepatic dysfunction secondary to viral infection (hepatitis B or C; Epstein Barr virus [EBV]; or cytomegalovirus [CMV]), or a history of diagnosed drug- or alcohol-induced hepatic toxicity or frank hepatitis.
    25. Patients with moderate to severe hepatic or renal impairment.
    26. Patients who have taken strong cytochrome P450 subtype 3A4 (CYP3A4) inhibitors or inducers within 4 weeks prior to Baseline or who anticipate requiring use of strong CYP3A4 inhibitors or inducers during the study
    1. El paciente ya ha participado anteriormente en estudios con tozadenant.
    2. El paciente está participando o ha participado en otro estudio y ha recibido un PEI en un período de cinco semividas del PEI.
    3. El paciente sufre una forma secundaria o atípica de Parkinson (por ejemplo, inducida por fármacos o posterior a un ACV).
    4. Indice de masa corporal (IMC) superior a 40.
    5. QTcF ≥ 500 ms durante la selección o un intervalo QTcF medio ≥ 450 ms en varones y ≥ 470 ms en mujeres en la visita basal del estudio.
    6. Diagnóstico conocido de melanoma maligno.
    7. Historial de intervención neuroquirúrgica para la EP, excepto implantación de electrodos para la estimulación profunda del cerebro al menos 12 meses, o más, antes de la selección. Los sujetos con estimulación cerebral profunda no deben estar experimentando efectos secundarios clínicamente significativos relacionados con el procedimiento, el dispositivo o la estimulación.
    8. hipertensión de grado 2 (TA sistólica ≥ 160 o TA diastólica ≥ 100 mmHg) tratada o no tratada .
    9. Paciente con historial de crisis hipertensa, excepto si se ha eliminado la causa subyacente
    10. El paciente tiene antecedentes de alcoholismo o drogadicción crónicos en los últimos dos años.
    11. El paciente tomaba apomorfina, budipino, istradefilina, tolcapona o DUOPA™/Duodopa® cuatro semanas antes de la selección, o es probable que necesite alguno de estos fármacos durante el estudio.
    12. El paciente recibe tratamientos antipsicóticos. No obstante, se permite la administración de quetiapina en dosis de ≤ 100 mg / día y pimavanserina si el paciente ha estado en una dosis diaria estable durante un mínimo de cuatro semanas antes de la selección. No se permite la administración PRN
    13. El paciente ha tomado digoxina durante las cuatro semanas previas a la selección o es probable que la necesite durante el estudio,
    14. Hipertiroidismo o hipotiroidismo, a menos que se cumplan las siguientes condiciones:
    a. El paciente ha recibido una dosis estable de medicación para la tiroides durante un mínimo de tres semanas antes de la visita Basal.
    b. Las concentraciones de TSH se encuentran dentro del intervalo normal (o dentro de un límite de ± 10 % del intervalo normal).
    c. El paciente es clínicamente eutiroideo.
    15. La presencia de cualquier valor de laboratorio fuera de los rangos normales durante la selección que los investigadores no hayan revisado ni documentado como no clínicamente significativo.
    16. Una puntuación < 26 en la segunda edición del mini examen del estado mental (MMSE-II) realizada en la visita de selección.
    17. Los pacientes con un episodio depresivo grave actual. Los pacientes que estén recibiendo tratamiento para la depresión con antidepresivos pueden participar en el estudio si han estado tomando una dosis diaria estable del antidepresivo durante al menos ocho semanas antes de la visita Basal.
    18. El paciente tiene un historial reciente de intento de suicidio (definido como un intento activo, interrumpido o frustrado ocurrido en los últimos cinco años) o mostró ideación suicida en los últimos seis meses, indicada por una respuesta positiva (“Sí”) a las preguntas 4 o 5 de la C-SSRS realizada en la visita de selección o basal.
    19. El paciente muestra signos de un trastorno del control de impulsos (ICD) (es decir, uno o más módulos positivos) de acuerdo con la Entrevista de Minnesota para los trastornos impulsivos modificada (mMIDI), a menos que una entrevista clínica estructurada realizada durante la selección confirme que los pacientes no padecen ningún ICD.
    20. La paciente actualmente en estado de lactancia o embarazada, o planificando quedarse embarazada durante la duración del estudio.
    21. El paciente tiene una hipersensibilidad conocida a algún componente del PEI o sus excipientes.
    22. Cualquier otro trastorno o hallazgo anormal clínicamente significativo detectado en la exploración física o neurológica, o en el historial psiquiátrico y clínico durante la visita de selección o basal que, según el criterio de los investigadores, impida la participación del paciente en el estudio, o ponga al paciente en un riesgo adicional o perjudique la evaluación de la seguridad y la eficacia del PEI.
    23. Los pacientes con niveles de alanina transaminasa (ALT) o aspartato transaminasa (AST) que 3x LSN, o una bilirrubina total que exceda en más de 1,5 veces el LSN durante la selección.
    24. Los pacientes con un historial de disfunción hepática derivada de una infección vírica (HBV, HCV, VEB o CMV), hepatotoxicidad o hepatitis franca inducidas por fármacos o alcohol.
    25.Pacientes con disfunción hepática o renal entre moderada y grave.
    26. Los pacientes que tomaron inhibidores o inductores fuertes de citocromo P450 subtipo 3A4 (CYP3A4) en las cuatro semanas previas a la visita Basal o que se prevea que pueden requerir el uso de inhibidores o inductores fuertes de CYP3A4 durante el período del estudio
    E.5 End points
    E.5.1Primary end point(s)
    1. Treatment emergent Adverse Events.
    2. Vital signs
    3. ECGs
    4. Clinical Laboratory tests
    5. Physical and neurological examinations
    E.5.1.1Timepoint(s) of evaluation of this end point
    End of treatment, assumed to be 52 weeks
    E.5.2Secondary end point(s)
    Epworth Sleepiness Scale ESS
    modified Minnesota Impulse Disorders Interview mMIDI
    Columbia Suicide Severity Rating Scale C-SSRS
    Unified Parkinson’s Disease Rating Scale (UPDRS) Part I - IV
    Clinical Global Impression of Improvement (CGI-I).
    Patient’s Global Impression of Improvement (PGI-I).
    Parkinson’s Disease Quality of Life Questionnaire (PDQ-39; total score and individual domain scores).
    Non-motor Symptom Questionnaire.
    EuroQol 5D-5L Health Questionnaire (EQ-5D-5L).
    Patient-completed diaries (Change from Baseline in the number of hours per day spent as follows: OFF time, ON time without troublesome dyskinesia, total ON time, ON time with troublesome dyskinesia and asleep time).
    Healthcare Resource Utilization.
    E.5.2.1Timepoint(s) of evaluation of this end point
    End of treatment, assumed to be 52 weeks
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA40
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    European Union
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 158
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 292
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state40
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 450
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients will return to standard of care under their neurologists
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-06-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-06-07
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands